BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

Adriana J. Rijnsburger; Inge-Marie A. Obdeijn; Reinoutje Kaas; Madeleine A. Tilanus-Linthorst; Carla Boetes; Claudette E Loo; Martin N. J. M. Wasser; Elisabeth Bergers; Theo Martinus de Kok; Sara H. Muller; Hans Peterse; Rob A. E. M. Tollenaar; Nicoline Hoogerbrugge; Sybren Meijer; Carina C. M. Bartels; Caroline Seynaeve; Maartje J. Hooning; Mieke Kriege; Paul I. M. Schmitz; Jan C. Oosterwijk; Harry J de Koning; Emiel J. T. Rutgers; Jan G. M. Klijn

doi:10.1200/JCO.2009.27.2294

BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

Adriana J. Rijnsburger, Inge-Marie A. Obdeijn, Reinoutje Kaas, Madeleine A. Tilanus-Linthorst, Carla Boetes, Claudette E Loo, Martin N. J. M. Wasser, Elisabeth Bergers, Theo Martinus de Kok, Sara H. Muller, Hans Peterse, Rob A. E. M. Tollenaar, Nicoline Hoogerbrugge, Sybren Meijer, Carina C. M. Bartels, Caroline Seynaeve, Maartje J. Hooning, Mieke Kriege, Paul I. M. Schmitz, Jan C. OosterwijkHarry J de Koning, Emiel J. T. Rutgers, Jan G. M. Klijn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

120 Citations (Web of Science)

Abstract

The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P

Original language	English
Pages (from-to)	5265-5273
Journal	Journal of Clinical Oncology
Volume	28
Issue number	36
DOIs	https://doi.org/10.1200/JCO.2009.27.2294
Publication status	Published - 20 Dec 2010

Access to Document

10.1200/JCO.2009.27.2294

Cite this

Rijnsburger, A. J., Obdeijn, I-M. A., Kaas, R., Tilanus-Linthorst, M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., de Kok, T. M., Muller, S. H., Peterse, H., Tollenaar, R. A. E. M., Hoogerbrugge, N., Meijer, S., Bartels, C. C. M., Seynaeve, C., Hooning, M. J., Kriege, M., Schmitz, P. I. M., ... Klijn, J. G. M. (2010). BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 28(36), 5265-5273. https://doi.org/10.1200/JCO.2009.27.2294

@article{1347dbfcf0ea4a4caf63db569ca77813,

title = "BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study",

abstract = "The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P",

author = "Rijnsburger, {Adriana J.} and Obdeijn, {Inge-Marie A.} and Reinoutje Kaas and Tilanus-Linthorst, {Madeleine A.} and Carla Boetes and Loo, {Claudette E} and Wasser, {Martin N. J. M.} and Elisabeth Bergers and {de Kok}, {Theo Martinus} and Muller, {Sara H.} and Hans Peterse and Tollenaar, {Rob A. E. M.} and Nicoline Hoogerbrugge and Sybren Meijer and Bartels, {Carina C. M.} and Caroline Seynaeve and Hooning, {Maartje J.} and Mieke Kriege and Schmitz, {Paul I. M.} and Oosterwijk, {Jan C.} and {de Koning}, {Harry J} and Rutgers, {Emiel J. T.} and Klijn, {Jan G. M.}",

year = "2010",

month = dec,

day = "20",

doi = "10.1200/JCO.2009.27.2294",

language = "English",

volume = "28",

pages = "5265--5273",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "36",

}

Rijnsburger, AJ, Obdeijn, I-MA, Kaas, R, Tilanus-Linthorst, MA, Boetes, C, Loo, CE, Wasser, MNJM, Bergers, E, de Kok, TM, Muller, SH, Peterse, H, Tollenaar, RAEM, Hoogerbrugge, N, Meijer, S, Bartels, CCM, Seynaeve, C, Hooning, MJ, Kriege, M, Schmitz, PIM, Oosterwijk, JC, de Koning, HJ, Rutgers, EJT & Klijn, JGM 2010, 'BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study', Journal of Clinical Oncology, vol. 28, no. 36, pp. 5265-5273. https://doi.org/10.1200/JCO.2009.27.2294

BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. / Rijnsburger, Adriana J.; Obdeijn, Inge-Marie A.; Kaas, Reinoutje et al.
In: Journal of Clinical Oncology, Vol. 28, No. 36, 20.12.2010, p. 5265-5273.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

AU - Rijnsburger, Adriana J.

AU - Obdeijn, Inge-Marie A.

AU - Kaas, Reinoutje

AU - Tilanus-Linthorst, Madeleine A.

AU - Boetes, Carla

AU - Loo, Claudette E

AU - Wasser, Martin N. J. M.

AU - Bergers, Elisabeth

AU - de Kok, Theo Martinus

AU - Muller, Sara H.

AU - Peterse, Hans

AU - Tollenaar, Rob A. E. M.

AU - Hoogerbrugge, Nicoline

AU - Meijer, Sybren

AU - Bartels, Carina C. M.

AU - Seynaeve, Caroline

AU - Hooning, Maartje J.

AU - Kriege, Mieke

AU - Schmitz, Paul I. M.

AU - Oosterwijk, Jan C.

AU - de Koning, Harry J

AU - Rutgers, Emiel J. T.

AU - Klijn, Jan G. M.

PY - 2010/12/20

Y1 - 2010/12/20

N2 - The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P

AB - The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival.Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR).Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P

U2 - 10.1200/JCO.2009.27.2294

DO - 10.1200/JCO.2009.27.2294

M3 - Article

C2 - 21079137

SN - 0732-183X

VL - 28

SP - 5265

EP - 5273

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 36

ER -